Department of Oncology, Division of Clinical Sciences, St George's University of London, London, UK.
Immunotherapy. 2011 Apr;3(4):507-16. doi: 10.2217/imt.11.18.
Therapies based on the use of autologous immune cells are among the best candidates for cancer immunotherapy. Dendritic cell vaccines have demonstrated very encouraging responses for some solid tumors, while in melanoma autologous T-cell therapies have exceeded 70% objective response rates in selected Phase I trials. However, it is clear that a number of barriers exist to the effective, practical application of these therapies. The aim of this article is to consider modifications to such strategies over the last 3 years and the resultant clinical research in autologous dendritic cell vaccines, T-cell therapy and γδ T-cell therapy for cancer.
基于自体免疫细胞使用的疗法是癌症免疫疗法的最佳候选者之一。树突状细胞疫苗已证明对某些实体瘤有非常令人鼓舞的反应，而在黑色素瘤中，自体 T 细胞疗法在选定的 I 期试验中超过了 70%的客观缓解率。然而，很明显，这些疗法的有效、实际应用存在许多障碍。本文旨在考虑过去 3 年来对这些策略的修改，以及随后在癌症的自体树突状细胞疫苗、T 细胞疗法和 γδ T 细胞疗法的临床研究。
